Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare liver cancer that displays features that make it very different in its behavior and clinical findings from conventional hepatocellular carcinoma (HCC)[1]. FL-HCC accounts for less than 1% of all primary hepatic malignancies. Unlike conventional HCC, FL-HCC is more common in younger patients and has a significantly lower incidence. This activity describes the evaluation and treatment of FL-HCC and highlights the role of an interprofessional team in evaluating and treating patients with this malignancy.
- Provider:StatPearls, LLC
- Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/22802
- Start Date: 2023-09-01 05:00:00
- End Date: 2023-09-01 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABS - 1.0 Point; Credit Type(s): Accredited CME (ABS)
ABPATH - 1.0 Point; Credit Type(s): Lifelong Learning (ABPATH)
ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
ABS - 1.0 Point; Credit Type(s): Self-Assessment (ABS) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Clinical Pathology, Complex General Surgical Oncology, Gastroenterology, General Surgery, GI (incl. Liver, Pancreas, Bilary), Medical Oncology, Surgical Pathology, Transplant Hepatology
Subscribe
Login
0 Comments
Oldest